Topics

Articles

The latest on its implementation—and the implications for biopharma.

IRA Journey Update

The Medicare Part D cap in 2025 won’t solve patients’ need for financial assistance.

Addressing Rx Affordability

New PC column explores commercialization trends and how pharma can adjust to the new squeeze of market, regulatory, pricing, and gross-to-net pressures.

Channel Fragmentation and Diversifying Product Archetypes

How current frameworks influence coverage decisions and pricing negotiations.

The Evolving Value Assessment Landscape in the US

The products, cloud revenue management solution provider says, are aimed at addressing supply chain challenges.

Model N’s Latest Enhancements Address Duplicate Discounts, Global Tender Management

Cost Plus Drug Co. adds J&J's Janssen medications to its offerings, increasing affordability for diabetes patients.

Mark Cuban's Cost Plus Drug Co. Expands to Offer J&J Brand-Name Medications

How various factors are affecting the amount of funds allocated to healthcare.

Assessing Drug Pricing in Europe

Pharma Commerce provides a look into a few of the conference’s highlights. 

PAP 2023: Where Patient Access and Adherence Meet Regulatory Policy

AmerisourceBergen exec explains how his experience in health policy analysis and data analytics helps him tackle patient access obstacles. 

PAP 2023: Corey Ford Discusses Experience in Tackling Reimbursement Challenges at Access PAP 2023

AmerisourceBergen exec dives into the shift in Medicare Part D patient requirements.

Market Access